相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
Jackson K. Mukonzo et al.
BMC INFECTIOUS DISEASES (2013)
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania
Sabina F. Mugusi et al.
ANTIVIRAL THERAPY (2012)
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans
Milimo Maimbo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE
S. Hodder et al.
HIV MEDICINE (2012)
Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania
Sabina Mugusi et al.
PLOS ONE (2012)
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study
G. Yimer et al.
PHARMACOGENOMICS JOURNAL (2012)
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals
Sandra G. Heil et al.
THERAPEUTIC DRUG MONITORING (2012)
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients
Marelize Swart et al.
Frontiers in Genetics (2012)
Contribution of N-Glucuronidation to Efavirenz Elimination In Vivo in the Basal and Rifampin-Induced Metabolism of Efavirenz
Doo-Yeoun Cho et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method
Eleni Aklillu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients
Abiy Habtewold et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
Getnet Yimer et al.
PLOS ONE (2011)
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
E. Gebeyehu et al.
PHARMACOGENOMICS JOURNAL (2011)
No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment
Juergen Burhenne et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients
E. Ngaimisi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection
Y. Jamshidi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients
Laure Elens et al.
PHARMACOGENOMICS (2010)
Presence of the CYP2B6 516G > T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
Verena Gounden et al.
AIDS RESEARCH AND THERAPY (2010)
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Jackson K. Mukonzo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
Anne-Sophie Belanger et al.
DRUG METABOLISM AND DISPOSITION (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Laboratory reference values for healthy adults from southern Tanzania
Elmar Saathoff et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2008)
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
Christopher Nyakutira et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy - Results of ACTG a5095
Bruce R. Schackman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers
Stephanie R. Faucette et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz:: the effect of gender, race, and CYP2B6 polymorphism
D Burger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Geography predicts neutral genetic diversity of human populations
F Prugnolle et al.
CURRENT BIOLOGY (2005)
Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers
SR Faucette et al.
DRUG METABOLISM AND DISPOSITION (2004)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
分享论文
